Literature DB >> 16078265

Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression.

Takahiko Naka1, Carsten Boltze, Doerthe Kuester, Torss-Oliver Schulz, Regine Schneider-Stock, Angela Kellner, Amir Samii, Christian Herold, Helmut Ostertag, Albert Roessner.   

Abstract

BACKGROUND: To the authors' knowledge, little is known regarding the alterations of G(1)-S checkpoint and their significance in chordoma, a rare bone tumor. The authors investigated the clinicopathologic relevance of cell cycle abnormalities in chordoma.
METHODS: The expression levels of p53, murine double minute 2 (MDM2), retinoblastoma protein (pRb), cyclin D1, p16(INK4a), and p27(Kip1) were investigated using immunohistochemical techniques; p53 mutations were studied by polymerase chain reaction (PCR)-single-strand conformation polymorphism, and mdm2 amplification was analyzed using real-time quantitative PCR. The results were compared with clinicopathologic parameters in 101 lesions.
RESULTS: Approximately 10-45% of primary tumors presented alterations of p53, MDM2, cyclin D1, and pRb proteins; most tumors lacked expression of p16(INK4a) and p27(Kip1). Alterations of p53, MDM2, cyclin D1, and pRb proteins were found to have cooperative effects on both higher proliferative ability (MIB-1 labeling index [LI]) and increased nuclear pleomorphism, a previously described prognostic indicator for patients with chordoma. Multivariate analyses revealed that, among these alterations, p53 overexpression was the only independent factor for higher MIB-1 LI. At the genetic level, mdm2 gene amplification was detected in 15.4% of the lesions but did not correlate with MDM2 overexpression or other clinicopathologic parameters. No p53 mutations were detected in the current series. Survival analysis revealed that p53 overexpression, but no other cell cycle alterations, was associated with a reduced overall survival.
CONCLUSIONS: Accumulation of cell cycle alterations led to an increased MIB-1 LI and nuclear pleomorphism, a previously described prognostic indicator in chordoma. The authors believe that p53 overexpression in particular is associated with an unfavorable prognosis in patients with chordoma. Copyright 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078265     DOI: 10.1002/cncr.21296

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Chordoma: an update on the pathophysiology and molecular mechanisms.

Authors:  Xin Sun; Francis Hornicek; Joseph H Schwab
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

2.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

3.  Expression and Therapeutic Potential of SOX9 in Chordoma.

Authors:  Hua Chen; Cassandra C Garbutt; Dimitrios Spentzos; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Clin Cancer Res       Date:  2017-06-12       Impact factor: 12.531

4.  Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.

Authors:  Mauro Longoni; Francesca Orzan; Michela Stroppi; Nicola Boari; Pietro Mortini; Paola Riva
Journal:  Neuro Oncol       Date:  2007-12-19       Impact factor: 12.300

5.  Recurrent chromosomal copy number alterations in sporadic chordomas.

Authors:  Long Phi Le; G Petur Nielsen; Andrew Eric Rosenberg; Dafydd Thomas; Julie M Batten; Vikram Deshpande; Joseph Schwab; Zhenfeng Duan; Ramnik J Xavier; Francis J Hornicek; A John Iafrate
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

6.  In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs.

Authors:  Takamitsu A Kato; Akihisa Tsuda; Mitsuru Uesaka; Akira Fujimori; Tadashi Kamada; Hirohiko Tsujii; Ryuichi Okayasu
Journal:  Radiat Oncol       Date:  2011-09-14       Impact factor: 3.481

7.  Frequent activation of EGFR in advanced chordomas.

Authors:  Barbara Dewaele; Francesca Maggiani; Giuseppe Floris; Michele Ampe; Vanessa Vanspauwen; Agnieszka Wozniak; Maria Debiec-Rychter; Raf Sciot
Journal:  Clin Sarcoma Res       Date:  2011-07-25

8.  A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12.

Authors:  Alexa Burger; Aleksandr Vasilyev; Ritu Tomar; Martin K Selig; G Petur Nielsen; Randall T Peterson; Iain A Drummond; Daniel A Haber
Journal:  Dis Model Mech       Date:  2013-12-05       Impact factor: 5.758

9.  On a Rare Cutaneous Metastasis from a Sacrococcygeal Chordoma.

Authors:  Alessandro D'Amuri; Matteo Brunelli; Federica Floccari; Francesco De Caro; Giuliana Crisman; Francesca Sanguedolce; Marcello Filotico
Journal:  Case Rep Pathol       Date:  2017-03-19

10.  Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation.

Authors:  K H Hallor; J Staaf; G Jönsson; M Heidenblad; F Vult von Steyern; H C F Bauer; M Ijszenga; P C W Hogendoorn; N Mandahl; K Szuhai; F Mertens
Journal:  Br J Cancer       Date:  2007-12-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.